Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1251-1259

  Pollock, Louisa ^a   Else, Laura ^b   Poerksen, Goenke ^a   Molyneux, Elizabeth ^a   Moons, Peter ^a   Walker, Sarah ^c   Fraser, William ^d   Back, David ^b   Khoo, Saye ^b  

^a UNIVERSITY OF MALAWI   (Malawi)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Africa; Paediatric; Triomune

Indexed keywords

AMOXICILLIN; CHLORAMPHENICOL; COTRIMOXAZOLE; FANSIDAR; FLUCLOXACILLIN; GRISEOFULVIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; TRIOMUNE 30; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALNUTRITION; MAXIMUM PLASMA CONCENTRATION; NUTRITIONAL STATUS; PRACTICE GUIDELINE; CHEMISTRY; DRUG COMBINATION; INFANT; MALAWI; ORAL DRUG ADMINISTRATION; PLASMA; PRESCHOOL CHILD; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALAWI; MALE; MALNUTRITION; NEVIRAPINE; PLASMA; STAVUDINE; TABLETS;

EID: 76249122103     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp358     Document Type: Article

References (29)

1. UNICEF/WHO Technical Consultation: Improving Access to Appropriate Paediatric ARV Formulations. Geneva: WHO, November 2004. Available at: http://www.who.int/3by5/en/finalreport.pdf (15 August 2009, date last accessed).
2. Committee on Pediatric AIDS, Section on International Child Health. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119: 838-45.
3. Ministry of Health and Population Malawi: National AIDS Commission. Treatment of AIDS. Guidelines for the Use of Antiretroviral Therapy in Malawi, First Edition. 2003.
4. Menson EN, Walker AS, Sharland M et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332: 1183-7.
5. WHO. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings, Towards Universal Access: Recommendations for a Public Health Approach. February 2006. Available at: http://www.unicef.org/aids/files/towards_universal_access_report_2008.pd f (15 August 2009, date last accessed).
6. Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian Pediatr 2005; 42: 789-96.
7. Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005; 41: 100-7.
8. O'Brien DP, Sauvageot D, Zachariah R et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006; 20: 1955-60.
9. Chokephaibulkit K, Plipat N, Cressey TR et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19: 1495-9.
10. Corbett A, Hosseinipour M, Nyirenda J et al. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract H-1106, p. 280. American Society for Microbiology, Washington, DC, USA.
11. Luzuriaga K, Bryson Y, McSherry G et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174: 713-21.
12. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet 1989; 17 Suppl 1: 68-88.
13. Jorquera F, Culebras JM, Gonzalez-Gallego J. Influence of nutrition on liver oxidative metabolism. Nutrition 1996; 12: 442-7.
14. Ellis JC, L'Homme RF, Ewings FM et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12: 253-60.
15. NCHS/WHO. Combined sex references. As per Malawi National Guidelines for the management of severe acute malnutrition. 1982.
16. Government of Malawi. Interim Guidelines for the Management of Acute Malnutrition Through Community Based Therapeutic Care. 2007.
17. de Onis M, Onyango AW, Van den Broeck J et al. Measurement and standardization protocols for anthropometry used in the construction of a new international growth reference. Food Nutr Bull 2004; 25: S27-36.
18. U.S. Department of Health and Human Services. Food and rug Administration. Centre for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Products - General Considerations. March 2003. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/ucm070124.pdf (15 August 2009, date last accessed).
19. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. July 2001. Available at: http://apps.who.int/prequal/info_applicants/BE/emea_bioequiv.pdf (15 August 2009, date last accessed).
20. Almond LM, Edirisinghe D, Dalton M et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78: 132-42.
21. Hollanders RM, van Ewijk-Beneken Kolmer EW, Burger DM et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744: 65-71.
22. La Porte CJL, Back DJ, Blaschke T et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 5-14.
23. Sharland M, Blanche S, Castelli G et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 Suppl 2: 61-86.
24. Poerksen G, Nyirenda M, Pollock L et al. Comparison of previous and present World Health Organization clinical staging criteria in HIV-infected Malawian children. AIDS 2009; 23: 1913-6.
25. National Statistical Office (NSO), Malawi. Malawi Demographic and Health Survey 2004. December 2005. Available at: http://www.measuredhs.com/pubs/pdf/FR175/FR-175-MW04.pdf (15 August 2009, date last accessed).
26. Fayet A, Beguin A, de Tejada BM et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30: 511-22.
27. L'Homme RF, Kabamba D, Ewings FM et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22: 557-65.
28. Mulenga V, Fillekes Q, Kabamba D et al. Pharmacokinetics of nevirapine in HIV-infected infants with body weight 3-6kg taking paediatric fixed dose combination tablets. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 881. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
29. Ministry of Health and Population Malawi: National AIDS Commission. Treatment of AIDS. Guidelines for the Use of Antiretroviral Therapy in Malawi, Third Edition. 2008.